134.31
前日終値:
$123.98
開ける:
$127.53
24時間の取引高:
1.05M
Relative Volume:
1.83
時価総額:
$8.81B
収益:
$3.55B
当期純損益:
$370.24M
株価収益率:
24.51
EPS:
5.48
ネットキャッシュフロー:
$355.96M
1週間 パフォーマンス:
+7.49%
1か月 パフォーマンス:
+11.41%
6か月 パフォーマンス:
-3.05%
1年 パフォーマンス:
-14.15%
Aptargroup Inc Stock (ATR) Company Profile
Compare ATR vs ISRG, BDX, RMD, MDLN, ALC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
ATR
Aptargroup Inc
|
134.31 | 8.14B | 3.55B | 370.24M | 355.96M | 5.48 |
|
ISRG
Intuitive Surgical Inc
|
488.15 | 169.16B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
210.02 | 58.84B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
RMD
Resmed Inc
|
271.63 | 38.90B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
47.30 | 38.45B | 27.43B | 1.27B | 1.01B | 1.5829 |
|
ALC
Alcon Inc
|
78.83 | 38.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
Aptargroup Inc Stock (ATR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-11-03 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-09-04 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2025-01-07 | 開始されました | Raymond James | Outperform |
| 2025-01-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-10-14 | アップグレード | Jefferies | Hold → Buy |
| 2024-04-29 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-01-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-08-02 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-14 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-10-14 | 開始されました | Seaport Global Securities | Neutral |
| 2020-04-27 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-03-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-03-04 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-02-26 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-07-08 | 開始されました | Morgan Stanley | Overweight |
| 2019-04-05 | 繰り返されました | BofA/Merrill | Underperform |
| 2019-02-27 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2018-05-18 | 開始されました | Jefferies | Hold |
| 2016-12-07 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2016-10-13 | 開始されました | Jefferies | Hold |
| 2016-01-05 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2015-11-02 | アップグレード | Deutsche Bank | Hold → Buy |
| 2015-09-15 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2015-05-01 | アップグレード | BofA/Merrill | Underperform → Neutral |
| 2013-02-19 | 繰り返されました | Deutsche Bank | Hold |
| 2013-01-08 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2012-07-10 | ダウングレード | KeyBanc Capital Mkts | Buy → Hold |
| 2012-04-11 | 開始されました | KeyBanc Capital Mkts | Buy |
| 2011-06-13 | アップグレード | KeyBanc Capital Mkts | Hold → Buy |
すべてを表示
Aptargroup Inc (ATR) 最新ニュース
APTARGROUP, INC. SEC 10-K Report - TradingView
AptarGroup Q4 2025 slides: Sales surge 14% while margins face pressure - Investing.com
Earnings call transcript: AptarGroup Q4 2025 earnings beat expectations, stock surges - Investing.com India
AptarGroup declares $0.48 dividend - MSN
How Strong Q4 Results and FX-Tied Guidance Will Impact AptarGroup (ATR) Investors - simplywall.st
Aptar Reports Fourth Quarter and Annual 2025 Results - Aptar
AptarGroup (ATR) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Aptar (ATR) Projects Growth and Strategic Investments for the Fu - GuruFocus
AptarGroup (ATR) Reports Strong Q4 Revenue Boosted by Segment Gr - GuruFocus
AptarGroup Inc (NYSE:ATR) Beats Q4 Revenue Estimates, Issues Cautious Q1 Outlook - Chartmill
AptarGroup (ATR) Q4 Earnings and Revenues Surpass Estimates - Yahoo Finance
AptarGroup: Fourth Quarter Earnings Overview - Bitget
AptarGroup Q4 Non-GAAP Earnings Fall, Revenue Rises; Shares Advance After Hours - marketscreener.com
AptarGroup: Q4 Earnings Snapshot - kens5.com
AptarGroup Inc. Reveals Drop In Q4 Income - Nasdaq
AptarGroup (ATR) Releases Q4 2025 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
(ATR) AptarGroup, Inc. Expects Q1 Adjusted EPS Range $1.13$1.21 - marketscreener.com
AptarGroup, Inc. Reports Fourth Quarter and Annual 2025 Results - TradingView
Cash Dividend On The Way From AptarGroup (ATR) - Nasdaq
AptarGroup, Inc. (ATR) Stock Analysis: Exploring The 27% Upside Potential For Investors - DirectorsTalk Interviews
Winners Losers: What is the dividend yield of AptarGroup IncPortfolio Profit Report & Safe Entry Point Alerts - baoquankhu1.vn
Trading Recap: Is AptarGroup Inc part of any major index2025 Performance Recap & Fast Moving Market Watchlists - baoquankhu1.vn
Earnings Preview: AptarGroup (ATR) Q4 Earnings Expected to Decline - Finviz
Is AptarGroup Inc.’s growth already priced inGlobal Markets & Intraday High Probability Alerts - Mfd.ru
City Council OKs AptarGroup tax abatements, delays Rankinen request - Midland Daily News
AptarGroup declares $0.48 quarterly dividend, sets annual meeting By Investing.com - Investing.com Australia
AptarGroup Keeps Quarterly Dividend at $0.48 a Share, Payable Feb. 25 to Shareholders of Record on Feb. 4 - marketscreener.com
AptarGroup declares $0.48 quarterly dividend, sets annual meeting - Investing.com
Aptar Declares Quarterly Dividend and Announces 2026 Annual Meeting Details - Aptar
Aptar Again Recognized with Prestigious 'A' Score on the CDP Cli - GuruFocus
Aptar Again Recognized with Prestigious ‘A’ Score on the CDP Climate Change Assessment - marketscreener.com
Surprises Report: Is AptarGroup Inc.’s growth already priced inWeekly Trading Summary & Low Drawdown Trading Strategies - baoquankhu1.vn
Fund Flows: Is AptarGroup Inc stock undervalued right now2025 Growth vs Value & Entry Point Confirmation Alerts - baoquankhu1.vn
Is the Options Market Predicting a Spike in AptarGroup Stock? - Nasdaq
Aptar's Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate - marketscreener.com
Aptar’s nasal delivery solutions used in CastleVax COVID-19 vaccine trial - Investing.com Nigeria
Aptar’s nasal delivery solutions used in CastleVax COVID-19 vaccine trial By Investing.com - Investing.com South Africa
Aptar’s Nasal Vaccine Delivery Solutions Featured in CastleVax Phase II Clinical Trial of an Intranasal COVID-19 Vaccine Candidate - Aptar
Nasal COVID-19 vaccine trial uses Aptar devices to test immunity levels - Stock Titan
Aptar's Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink - marketscreener.com
AptarGroup Unveils Innovative Eye Drop Delivery System in Strategic Partnership - AD HOC NEWS
AptarGroup, Inc. (ATR) Stock Analysis: Eyeing A 28.5% Upside With Strong Analyst Support - DirectorsTalk Interviews
Aptar’s Eye Care Solutions Designed to Improve Dosing Precision, Including Newest Technology, Beat the Blink™ - Aptar
Aptargroup Inc (ATR) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):